AMENDMENTS TO THE CLAIMS

- 1. (original) A peptide which comprises any one of the amino acid sequences selected from a group consisting of:
- Arg Tyr Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 2),
- Arg Tyr Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 3),
- Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 4),
- Ala Tyr Leu Pro Ala Val Pro Ser Leu (SEQ ID NO: 5), and
- Asn Tyr Met Asn Leu Gly Ala Thr Leu (SEQ ID NO: 6).
- 2. (original) The peptide according to claim 1, which consists of any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6.
- 3. (original) A peptide which comprises an altered amino acid sequence wherein an alteration of an amino acid residue is comprised in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6, and which has an activity to induce a CTL in an HLA-A24-restricted manner, except for a peptide comprising the amino acid of SEQ ID NO: 7.
- 4. (original) The peptide according to claim 3, which comprises an altered amino acid sequence wherein leucine at position 9 in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 5, and 6 is substituted by phenylalanine, tryptophan, isoleucine, or methionine.

- 5. (original) The peptide according to claim 3, which comprises an altered amino acid sequence wherein phenylalanine at position 9 in the amino acid sequence of SEQ ID NO: 4 is substituted by tryptophan, leucine, isoleucine, or methionine.
- 6. (original) The peptide according to claim 3, which comprises an altered amino acid sequence wherein cysteine at position 5 in the amino acid sequence of SEQ ID NO: 4 is substituted by alanine, serine, or α -aminobutyric acid (SEQ ID NO: 66, 67, or 68).
 - 7. canceled.
- 8. (currently amended) A polynucleotide which encodes the peptide according to any one of claims 1 to 76.
 - 9. canceled
- 10. (currently amended) An expression vector which contains comprises the polynucleotide of claim 8 or 9.
- 11. (currently amended) A cell which comprises the expression vector of claim 10an expression vector comprising a polynucleotide encoding the peptide of claim 1 or claim 3.
- 12. (currently amended) A process for preparing a peptide according to any one of claims 1 to 7 which comprises any one of

the amino acid sequences selected from a group consisting of:

Arg Tyr Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 2),

Arg Tyr Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 3),

Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 4),

Ala Tyr Leu Pro Ala Val Pro Ser Leu (SEQ ID NO: 5), and

Asn Tyr Met Asn Leu Gly Ala Thr Leu (SEQ ID NO: 6), or which comprises an altered amino acid sequence wherein an alteration of an amino acid residue is comprised in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3,

4, 5, and 6, and which has an activity to induce a CTL in an HLA-A24-restricted manner, except for a peptide comprising the amino acid of SEQ ID NO: 7, which comprises culturing the cell according to claim 11 in a condition operable for the expression of peptides.

- 13. (currently amended) An antibody which specifically binds to the peptide according to any one of claims 1 to 7claim 1.
- 14. (currently amended) An antigen-presenting cell on which a complex between a cancer antigen peptide derived from the peptide according to any one of claims 1 to 7claim 1 or claim 3 and an HLA-A24 antigen is presented.
- 15. (original) The antigen-presenting cell according to claim 14, on which a complex between a cancer antigen peptide consisting of any one of the amino acid sequences selected from

the group consisting of SEQ ID NOs: 2 to 6 and 66 to 68 and an HLA-A24 antigen is presented.

)

- 16. (currently amended) A CTL which recognizes a complex between a cancer antigen peptide derived from the peptide according to any one of claims 1 to 7 claim 1 or claim 3 and an HLA-A24 antigen.
- 17. (original) The CTL according to claim 16, which recognizes a complex between a cancer antigen peptide consisting of any one of the amino acid sequences selected from the group consisting of SEQ ID NOs: 2 to 6 and 66 to 68 and an HLA-A24 antigen.
- 18. (currently amended) A pharmaceutical composition which comprises the peptide according to any one of claims 1 to 7claim 1 or claim 3, the polynucleotide according to claim 8 or 9, the expression vector according to claim 10, the cell according to claim 11, the antigen-presenting cell according to claim 14 or 15, or the CTL according to claim 16 or 17, together with a pharmaceutically acceptable carrier.
- 19. (currently amended) A cancer vaccine which comprises as an effective ingredient the peptide according to any one of claims 1 to 7claim 1, the polynucleotide according to claim 8 or 9, the expression vector according to claim 10, the cell according to claim 11, the antigen-presenting cell according to

claim 14 or 15, or the CTL according to claim 16 or 17.

- 20. canceled.
- 21. (currently amended) A method for treatment prevention of a cancer, which comprises administering therapeutically or prophylactically effective amount of the peptide according to any one of claims 1 to 7, the polynucleotide according to claim 8 or 9, the expression vector according to claim 10, the cell according to claim 11, the antigen-presenting cell according to claim 14 or 15, or the CTL according to claim 16 or 17, claim 1 or claim 3 to a cancer patient in need who is positive for an HLA-A24, and positive for WT1.
- 22. (original) A pharmaceutical composition which comprises any one of the substances selected from the group consisting of:
 a) a peptide which comprises the sequence of Arg Val Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 7),
- b) a polynucleotide which encodes the peptide as shown above a),
- c) an expression vector which comprises the polynucleotide as shown above b),
- d) a cell which comprises the expression vector as shown abovec),
- e) an antigen-presenting cell on which a complex between a cancer antigen peptide derived from the peptide as shown above a) and an HLA-A24 antigen is presented, and
- f) a CTL which recognizes a complex between a cancer antigen

peptide derived from the peptide as shown above a) and an HLA-A24 antigen,

together with a pharmaceutically acceptable carrier.

- 23. canceled.
- 24. canceled.
- 25. (original) A method for treatment or prevention of a cancer, which comprises administering a therapeutically or prophylactically effective amount of any one of the substances selected from the group consisting of:
- a) a peptide which comprises the sequence of Arg Val Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 7),
- b) a polynucleotide which encodes the peptide as shown above a),
- c) an expression vector which comprises the polynucleotide as shown above b),
- d) a cell which comprises the expression vector as shown above c),
- e) an antigen-presenting cell on which a complex between a cancer antigen peptide derived from the peptide as shown above a) and an HLA-A24 antigen is presented, and
- f) a CTL which recognizes a complex between a cancer antigen peptide derived from the peptide as shown above a) and an HLA-A24 antigen,

to a cancer patient in need who is positive for an HLA-A24, and positive for WT1

- 26. (new) A pharmaceutical composition which comprises the polynucleotide encoding a peptide according to claim 1 or claim 3 and a pharmaceutically acceptable carrier.
- 27. (new) A pharmaceutical composition which comprises an expression vector encoding a peptide according to claim 1 or claim 3 and a pharmaceutically acceptable carrier.
- 28. (new) A pharmaceutical composition which comprises the cell according to claim 11 and a pharmaceutically acceptable carrier.
- 29. (new) A pharmaceutical composition which comprises the antigen-presenting cell according to claim 14 and a pharmaceutically acceptable carrier.
- 30. (new) A pharmaceutical composition which comprises the CTL according to claim 16 and a pharmaceutically acceptable carrier.
- 31. (new) A cancer vaccine which comprises the expression vector according to claim 10.
- 32. (new) A cancer vaccine which comprises the antigenpresenting cell according to claim 14.

- 33. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the expression vector according to claim 10 to a cancer patient who is positive for HLA-A24 and positive for WT1.
- 34. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the cell according to claim 11 to a cancer patient who is positive for HLA-A24 and positive for WT1.
- 35. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the antigen-presenting cell according to claim 14 to a cancer patient who is positive for HLA-A24 and positive for WT1.
- 36. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the CTL according to claim 16 to a cancer patient who is positive for HLA-A24 and positive for WT1.